Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Year range
1.
An. acad. bras. ciênc ; 71(2): 189-201, jun. 1999. ilus, graf
Article in English | LILACS | ID: lil-234513

ABSTRACT

Although recently developed drugs have brought significant improvement, the treatment of psychotic disorders still presents serious drawbacks. Since inherent complexity and lack of satisfactory understanding of the underlying pathophysiology impose limits for rational drug design, resourceful approaches in the search for antipsychotics are pertinent. This paper reports pharmacological properties of alstonine, a heteroyohimbine type alkaloid, Which exbitited an antipsychotic-like profile, inhibiting amphetamine-induced lethaly, apomorphine-induced steotypy and potentiating barbiturate-induced slleping time. Atypical features of alstonine were the prevention of haloperidol-induced catalepsy and lack of direct interaction with D1, D2 and 5-HT2A receptors, classically linked to antipsychotic mechanism of action.


Subject(s)
Animals , Male , Mice , Antipsychotic Agents/pharmacology , Plants, Medicinal , Secologanin Tryptamine Alkaloids/pharmacology , Amphetamine/antagonists & inhibitors , Apomorphine/antagonists & inhibitors , Barbiturates/antagonists & inhibitors , Central Nervous System Stimulants/antagonists & inhibitors , Chlorpromazine/pharmacology , Clozapine/pharmacology , Diazepam/pharmacology , Emetics/antagonists & inhibitors , Haloperidol/pharmacology , Hypnotics and Sedatives/antagonists & inhibitors , Nigeria , Pentobarbital/pharmacology , Reserpine/pharmacology , Sleep/drug effects , Stereotyping , Sulpiride/pharmacology
2.
Gac. méd. Méx ; 129(2): 119-23, mar.-abr. 1993. ilus, tab
Article in Spanish | LILACS | ID: lil-177100

ABSTRACT

Existen numerosas substancias, de estructura química diversa que han sido utilizadas como inductoras de sueño. Sin embargo, debido a que producen efectos colaterales indeseables, constantemente son substituidas por fármacos de reciente creación. Este trabajo se llevó a cabo con el propósito de analizar el efecto sobre el sueño de una beta lactama de 1.5 benzodiazepina, administrada intraperitonealmente (0.9 mg/kg) a ratas wistar. Los resultados indican que esta substancia incrementa de manera significativa, tanto al sueño lento como al paradójico a expensas de la vigilia. La lactancia de la primera fase de sueño paradójico, se prolonga significativamente. Se concluye que esta substancia facilita la presencia de sueño, manifestándose su acción durante un período relativamente largo


Subject(s)
Animals , Rats , Barbiturates/antagonists & inhibitors , Benzodiazepines/antagonists & inhibitors , Diazepam/pharmacology , Electromyography/methods , Flurazepam , Hypnotics and Sedatives/pharmacology , Nitrazepam , Pentobarbital/pharmacokinetics , Sleep Initiation and Maintenance Disorders/physiopathology , Sleep , Temazepam
SELECTION OF CITATIONS
SEARCH DETAIL